US2010297068A1PendingUtilityA1

Methods for treating viral infection using il-28 and il-29

72
Assignee: ZYMOGENETICS INCPriority: Oct 23, 2002Filed: Oct 29, 2009Published: Nov 25, 2010
Est. expiryOct 23, 2022(expired)· nominal 20-yr term from priority
A61P 7/00A61P 31/20A61P 31/12A61P 31/14A61K 38/20A61P 1/16A61K 47/60C07K 14/54A61K 38/21Y02A50/30
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

Claims

exact text as granted — not AI-modified
1 . A method of treating a West Nile virus infection in a mammal comprising administering to the mammal a therapeutically effective amount of a polypeptide comprising an amino acid sequence having at least 95% sequence identity to amino acid residues 20-200 of SEQ ID NO:4, and wherein after administration of the polypeptide the West Nile virus infection is reduced. 
     
     
         2 . The method of  claim 1  wherein the polypeptide is conjugated to a polyalkyl oxide moiety. 
     
     
         3 . The method of  claim 2  wherein the polyalkyl oxide moiety is a polyethylene glycol. 
     
     
         4 . The method of  claim 1  wherein the polypeptide comprises the amino acid sequence of SEQ ID NOs:4, 20, 32, 34 or 38.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.